Table 1 Characteristics of included studies
Characteristic | Data |
|---|---|
Use of medication: n (%) | |
Pharmacological | 212 (53.8) |
Non-pharmacological | 182 (46.2) |
Intervention type: n (%) | |
Educational | 40 (10.2) |
Mobile health | 55 (14.0) |
Counseling | 96 (24.4) |
Electronic | 15 (3.8) |
Change in healthcare delivery | 182 (46.2) |
Incentives | 17 (4.3) |
Peer support | 13 (3.3) |
Psychotherapy | 40 (10.2) |
Outreach | 23 (5.8) |
Type of trial: n (%) | |
Factorial | 15 (3.8) |
Multi-arm | 79 (20.1) |
Crossover | 23 (5.8) |
Income level: n (%) | |
High | 164 (42.6) |
Upper middle | 62 (15.7) |
Lower middle | 65 (16.5) |
Low | 34 (8.6) |
Mixed | 69 (17.5) |
WHO region: n (%) | |
Africa | 127 (32.2) |
Americas | 124 (31.5) |
Eastern Mediterranean | 6 (1.5) |
Europe | 43 (11.9) |
South East Asia | 17 (4.3) |
Western Pacific | 14 (3.6) |
Mixed | 63 (16.0) |
Participant type: n (%) | |
Black people | 39 (10.0) |
Men who have sex with men | 21 (5.3) |
Women | 65 (16.5) |
Youth | 24 (6.1) |
People who inject drugs | 25 (6.3) |
Prisoners | 9 (2.3) |
Transgender people | 2 (0.5) |
Children | 18 (4.6) |
Participant comorbidities: n (%) | |
TB | 22 (5.6) |
Mental health | 14 (3.6) |
Substance use | 34 (8.6) |
Cancer | 6 (1.5) |
Source of funding: n (%) | |
Industry alone | 45 (11.4) |
Non-industry | 300 (76.1) |
Both | 20 (7.4) |
Trial sites | |
Single center | 125 (31.7) |
Multi-center | 269 (66.3) |
Trial sites: median (Q1; Q3)* | 3 (1;7) |
Duration of follow-up (months): mean (SD) | 11.2 (9.7) |